Company News »

Harvard Apparatus Regenerative Technology’s HART-Trachea Spotlighted in a WCVB-TV News Segment

Business Wire
Share on StockTwits
Published on

Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART) , a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was spotlighted in a news segment which aired on Monday, February 24 on ABC television affiliate WCVB-TV 5 in Boston.

To view the news segment in its entirety, please visit the following link: http://www.wcvb.com/health/organs-grown-using-patients-cells/31441918

The video at the link above is provided for informational purposes only. Harvard Apparatus Regenerative Technology, Inc. is not responsible for the content of the linked video.

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the HART-Trachea, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our HART-Trachea technology has been used in six human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

Forward-Looking Statements

Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include, but are not limited to, statements relating to the regulatory approval of the HART-Trachea or any other HART products, by the FDA, EMA, MHRA or otherwise, which such approvals may not be obtained on a timely basis or at all; success with respect to patient surgeries involving HART products; any clinical trials, commercialization efforts and other regulatory or marketing approval efforts pertaining to HART’s products as well as the success thereof. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, factors described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Share on StockTwits

What others are reading on Finances

Sorry. No data so far.


Iron FX 1.11156/1.11128 2.8
XM Markets 1.09948/1.09928 2
FxPro 1.10184/1.10171 1.3
FXCM 1.13943/1.13912 3.1